Cargando…

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuoka, Shota, Kojima, Takashi, Koga, Yoshikatsu, Yamauchi, Mayumi, Komatsu, Masayuki, Komatsuzaki, Rie, Sasaki, Hiroki, Yasunaga, Masahiro, Matsumura, Yasuhiro, Doi, Toshihiko, Ohtsu, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355242/ https://www.ncbi.nlm.nih.gov/pubmed/28038457 http://dx.doi.org/10.18632/oncotarget.14209

Ejemplares similares

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
por: Kojima, Takashi, et al.
Publicado: (2018)

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
por: Fukuoka, Shota, et al.
Publicado: (2023)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018)

Correlation Functions in N=4 SYM and Integrability - 1
por: Komatsu, Shota
Publicado: (2018)

Correlation Functions in N=4 SYM and Integrability - 3
por: Komatsu, Shota
Publicado: (2018)

Correlation Functions in N=4 SYM and Integrability - 4
por: Komatsu, Shota
Publicado: (2018)

Correlation Functions in N=4 SYM and Integrability - 2
por: Komatsu, Shota
Publicado: (2018)

Structure Constants in $\mathcal{N}=4$ SYM at Finite Coupling as Worldsheet $g$-Function
por: Jiang, Yunfeng, et al.
Publicado: (2019)

Large charges on the Wilson loop in $ \mathcal{N} $ = 4 SYM: matrix model and classical string
por: Giombi, Simone, et al.
Publicado: (2021)

Large charges on the Wilson loop in $ \mathcal{N} $ = 4 SYM. Part II. Quantum fluctuations, OPE, and spectral curve
por: Giombi, Simone, et al.
Publicado: (2022)

William George Sym
Publicado: (1938)

Syms Operating Theatre
Publicado: (1890)

ET-05 PRECLINICAL STUDY OF AN ANTI-HUMAN TISSUE FACTOR ANTIBODY-DRUG CONJUGATE IN A MALIGNANT GLIOMA XENOGRAFT MODEL
por: Takashima, Hiroki, et al.
Publicado: (2019)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Sym-bolon : ensayos sobre cultura, religión y arte /
Publicado: (2005)

Instant SymPy starter: learn to use SymPy's symbolic engine to simplify Python calculations
por: Lamy, Ronan
Publicado: (2013)

Imaging mass spectrometry for the precise design of antibody-drug conjugates
por: Fujiwara, Yuki, et al.
Publicado: (2016)

Evaluation of the antitumor mechanism of antibody‐drug conjugates against tissue factor in stroma‐rich allograft models
por: Tsumura, Ryo, et al.
Publicado: (2019)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

On Stringy Thresholds in SYM/AdS Thermodynamics
por: Barbon, J.L.F., et al.
Publicado: (1998)

SymTrees and Multi-Sector QFTs
por: Baume, Florent, et al.
Publicado: (2023)

Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors
por: Koga, Yoshikatsu, et al.
Publicado: (2019)

Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis
por: Sato, Ryuta, et al.
Publicado: (2014)

The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution
por: Yasunaga, Masahiro, et al.
Publicado: (2013)

Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models
por: Yamamoto, Yoshiyuki, et al.
Publicado: (2015)

Bootstrapping correlation functions in N=4 SYM
por: Chicherin, Dmitry, et al.
Publicado: (2015)

Energy-energy correlations in N=4 SYM
por: Belitsky, A.V., et al.
Publicado: (2013)

Black hole cohomologies in N=4 SYM
por: Kim, Seok
Publicado: (2023)

Higher spin holography for SYM in d dimensions
por: Morales, J.F., et al.
Publicado: (2004)

S-duality and boundary conditions in N=4 SYM
por: Davide Gaiotto
Publicado: (2008)

Five-loop Konishi in N=4 SYM
por: Eden, Burkhard, et al.
Publicado: (2012)

An in Vitro Assay of hERG K(+) Channel Potency for a New EGFR Inhibitor FHND004
por: Jin, Tao, et al.
Publicado: (2018)

Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
por: Yasunaga, Masahiro, et al.
Publicado: (2017)

Current correlators in the Coulomb branch of N=4 SYM
por: Brandhuber, Andreas, et al.
Publicado: (2000)

Instability of Non-Commutative SYM Theories at Finite Temperature
por: Landsteiner, Karl, et al.
Publicado: (2001)

Properties of the Konishi multiplet in N=4 SYM theory
por: Bianchi, Massimo, et al.
Publicado: (2001)

Super Background Field Method for N=2 SYM
por: Grassi, Pietro A., et al.
Publicado: (2003)

Generation of three human induced pluripotent stem cell sublines (UCLAi004-A, UCLAi004-B, and UCLAi004-C) for reproductive science research
por: Pandolfi, Erica C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_abdk43lg138h804pcknvsdcenm